NDC 0378-0722-05 - Tizanidine
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0378-0722
- Requested NDC
- 0378-0722-05
- Package NDCs from labels
- 0378-0722-19, 0378-0722-05
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Effective date
- 2013-11-13
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Tizanidine - Mylan Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. | 2013-11-13 | HUMAN PRESCRIPTION DRUG LABEL |
| National Council for Prescription Drug Programs indexing - billing unit | National Council for Prescription Drug Programs | 2012-07-24 | Indexing - Billing Unit |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0378-0722-05 | EA - Each | 0378-0722 | 99ca6fd8-2282-4169-af36-3c2471fb4e7e | 1 | 2012-07-24 |
| 0378-0722-19 | EA - Each | 0378-0722 | 062a04b2-fbea-49a1-a1f9-921408c420e9 | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| TIZANIDINE HYDROCHLORIDE | ACTIVE INGREDIENT | B53E3NMY5C | TIZANIDINE TABLET [MYLAN PHARMACEUTICALS INC.] | 4 | |
| TIZANIDINE | ACTIVE MOIETY | 6AI06C00GW | TIZANIDINE TABLET [MYLAN PHARMACEUTICALS INC.] | 4 | |
| ANHYDROUS LACTOSE | INACTIVE INGREDIENT | 3SY5LH9PMK | TIZANIDINE TABLET [MYLAN PHARMACEUTICALS INC.] | 4 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | TIZANIDINE TABLET [MYLAN PHARMACEUTICALS INC.] | 4 | |
| CROSCARMELLOSE SODIUM | INACTIVE INGREDIENT | M28OL1HH48 | TIZANIDINE TABLET [MYLAN PHARMACEUTICALS INC.] | 4 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | TIZANIDINE TABLET [MYLAN PHARMACEUTICALS INC.] | 4 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | TIZANIDINE TABLET [MYLAN PHARMACEUTICALS INC.] | 4 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| tizanidine hydrochloride | TIZANIDINE HYDROCHLORIDE | Advagen Pharma Limited | 7f39499a-98cf-4d13-9b07-ccb5c22e43c8 | 2026-11-04 | Warnings, Adverse reactions | B53E3NMY5C |
| Tizanidine | TIZANIDINE | American Health Packaging | 3670f9e3-988d-48e6-9df0-d403d699e08a | 2026-10-30 | Warnings, Adverse reactions | B53E3NMY5C |
| Tizanidine | TIZANIDINE | PD-Rx Pharmaceuticals, Inc. | fd16a25c-67b6-ae6c-e053-6394a90aeee0 | 2026-10-28 | Warnings, Adverse reactions | B53E3NMY5C |
| Tizanidine | TIZANIDINE | PD-Rx Pharmaceuticals, Inc. | fdf4f09d-4537-a438-e053-6394a90a573d | 2026-10-28 | Warnings, Adverse reactions | B53E3NMY5C |
| Tizanidine | TIZANIDINE | St. Mary's Medical Park Pharmacy | cfd52c0c-a7c2-e23d-e053-2a95a90abbd1 | 2026-10-23 | Warnings, Adverse reactions | B53E3NMY5C |
| Tizanidine | TIZANIDINE | REMEDYREPACK INC. | 17ca23af-c88f-4235-930a-d7568051696f | 2026-10-15 | Warnings, Adverse reactions | B53E3NMY5C |
| tizanidine | TIZANIDINE | Cardinal Health 107, LLC | eeb18068-75c8-42d0-a006-1b134648333f | 2026-10-06 | Warnings, Adverse reactions | B53E3NMY5C |
| TIZANIDINE HYDROCHLORIDE | TIZANIDINE HYDROCHLORIDE | Preferred Pharmaceuticals Inc. | ae9b6808-632f-4204-8581-bf146dcab69f | 2026-10-05 | Warnings, Adverse reactions | B53E3NMY5C |
| TIZANIDINE HYDROCHLORIDE | TIZANIDINE HYDROCHLORIDE | Preferred Pharmaceuticals Inc. | 6439a7ef-1b22-4fa1-9be3-eedd3cd24191 | 2026-10-05 | Warnings, Adverse reactions | B53E3NMY5C |
| Tizanidine | TIZANIDINE | Preferred Pharmaceuticals, Inc. | 32c3be66-5398-425c-ac65-e57ba819bb43 | 2026-10-05 | Warnings, Adverse reactions | B53E3NMY5C |
| tizanidine | TIZANIDINE | Preferred Pharmaceuticals Inc. | f0e4eb26-6733-4df6-bb3c-86bf4d976f42 | 2026-10-05 | Warnings, Adverse reactions | B53E3NMY5C |
| Tizanidine | TIZANIDINE | Preferred Pharmaceuticals Inc. | 3c993e3c-ee52-45a7-be39-60eaac7a1092 | 2026-10-02 | Warnings, Adverse reactions | B53E3NMY5C |
| Tizanidine | TIZANIDINE | A-S Medication Solutions | 180985f0-3fbd-4868-a826-b84101618a03 | 2026-10-01 | Warnings, Adverse reactions | B53E3NMY5C |
| Tizanidine Hydrochloride | TIZANIDINE HYDROCHLORIDE | Apotex Corp. | 3dd09a0d-a782-1d6d-a552-b71e5bcbf2fe | 2026-09-18 | Warnings, Adverse reactions | B53E3NMY5C |
| tizanidine | TIZANIDINE | Apotex Corp. | 01c0d3d3-2373-a1b7-822a-80a66291a248 | 2026-09-18 | Warnings, Adverse reactions | B53E3NMY5C |
| Lymph Tonic II | ECHINACEA (ANGUSTIFOLIA), COLLINSONIA CANADENSIS, PHYTOLACCA DECANDRA, KALI IODATUM, PINUS SYLVESTRIS, PIX LIQUIDA, FERRUM PHOSPHORICUM, AESCULUS HIPPOCASTANUM, BARYTA CARBONICA, BERBERIS VULGARIS, CALCAREA CARBONICA, CALCAREA PHOSPHORICA, CAUSTICUM, HEPAR SULPHURIS CALCAREUM, KREOSOTUM, LYCOPODIUM CLAVATUM, MERCURIUS SOLUBILIS, NATRUM MURIATICUM, NITRICUM ACIDUM, PHOSPHORUS, PULSATILLA (PRATENSIS), SILICEA, STELLARIA MEDIA, SULPHUR, TEREBINTHINA, THUJA OCCIDENTALIS, BUFO RANA | BioActive Nutritional, Inc. | 0e3265b0-b210-4a4c-80d2-8a9712981d4e | 2026-09-17 | Warnings | ETJ7Z6XBU4 |
| tizanidine hydrochloride | TIZANIDINE HYDROCHLORIDE | PD-Rx Pharmaceuticals, Inc. | e19f83b8-8c59-415c-a744-7473d46ab0ca | 2026-09-16 | Warnings, Adverse reactions | B53E3NMY5C |
| tizanidine hydrochloride | TIZANIDINE HYDROCHLORIDE | PD-Rx Pharmaceuticals, Inc. | e94aa8b1-74ed-46b7-94c5-53d5d5630be6 | 2026-09-16 | Warnings, Adverse reactions | B53E3NMY5C |
| tizanidine hydrochloride | TIZANIDINE HYDROCHLORIDE | PD-Rx Pharmaceuticals, Inc. | d7d5dce0-f8a2-404d-9e87-e2235f5d3268 | 2026-09-16 | Warnings, Adverse reactions | B53E3NMY5C |
| Psoriasis Control | CENTELLA ASIATICA, SODIUM CHLORIDE, AND SILICON DIOXIDE | Forces of Nature | 2db33771-0bb9-49f8-84fa-dddc28e4ba26 | 2026-09-04 | Warnings | ETJ7Z6XBU4 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.